Kisspeptin Source

The sources, indexed

Kisspeptin references: every source behind the digest, indexed.

The peer-reviewed record this site reads from — DOIs and PubMed identifiers for each cited study, sortable by year and setting.

Back to the researchRead the effects page

How to read this list

Every numbered marker across this site maps to one entry below. The sources are the published kisspeptin literature — human Phase 1/2 trials, the genetics and electrophysiology that defined the mechanism, the pharmacokinetic comparisons of the two isoforms, and the reviews that map the field. Each entry carries its authors, journal, year, and a DOI or PubMed link so any claim can be traced to its origin. No claim on this site exists without a source in this index.

  1. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. ↗
  2. Liu X, Lee K, Herbison AE. Kisspeptin excites gonadotropin-releasing hormone neurons through a phospholipase C/calcium-dependent pathway regulating multiple ion channels. Endocrinology. 2008;149(9):4605-4614. ↗
  3. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. ↗
  4. Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014;99(6):E953-E961. ↗
  5. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-3331. ↗
  6. Mills EG, Abbara A, Dhillo WS, et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025;115:105689. ↗
  7. Velmurugan H, Mannava AS, Thangaraju P, Neelambaran K. Kisspeptin and its current clinical status - a systematic review. Curr Med Chem. 2025;32:1313-1322. ↗
  8. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. ↗
  9. Jayasena CN, Comninos AN, De Silva A, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod. 2015;30(8):1934-1941. ↗
  10. Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. ↗
  11. Jayasena CN, et al. Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. PLoS One. 2017;12(5):e0176821. ↗
  12. Scott G, Ahmad I, Howard K, MacLean D, Oliva C, Warrington S, Wilbraham D, Worthington P. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men. Br J Clin Pharmacol. 2013;75:381-391. ↗
  13. Rehman R, Zafar A, Ali AA, Baig M, Alam F. Impact of serum and follicular fluid kisspeptin and estradiol on oocyte maturity and endometrial thickness among unexplained infertile females during ICSI. PLoS One. 2020;15:e0239142. ↗
  14. Morrison AE, Fleming S, Levy MJ. A review of the pathophysiology of functional hypothalamic amenorrhoea in women subject to psychological stress, disordered eating, excessive exercise or a combination of these factors. Clin Endocrinol (Oxf). 2021;95:229-238. ↗
  15. Phylactou M, Clarke SA, Patel B, Baggaley C, Jayasena CN, Kelsey TW, Comninos AN, Dhillo WS, et al. Clinical and biochemical discriminants between functional hypothalamic amenorrhoea (FHA) and polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2021;95:239-252. ↗
  16. Abbara A, Al-Memar M, Phylactou M, et al. Kisspeptin in the prediction of pregnancy complications. Front Endocrinol (Lausanne). 2022;13:942664. ↗
  17. Sato K, et al. Potent vasoconstrictor kisspeptin-10 induces atherosclerotic plaque progression and instability: reversal by its receptor GPR54 antagonist. J Am Heart Assoc. 2017;6(4):e005790. ↗
  18. Mills EG, Comninos AN, Dhillo WS, et al. Kisspeptin administration stimulates reproductive hormones but does not affect anxiety in humans. J Clin Endocrinol Metab. 2025;110:dgaf128. ↗